<DOC>
	<DOCNO>NCT02519855</DOCNO>
	<brief_summary>The study evaluate immunogenicity , safety , tolerability ZOSTAVAX™ Vaccine ( V211 ) administer concomitantly versus nonconcomitantly Quadrivalent Influenza Virus vaccine ( inactivate ) participant ≥50 year age . The primary hypothesis test 1 ) noninferiority concomitant versus nonconcomitant vaccination regard Varicella zoster virus ( VZV ) Geometric Mean Titer ( GMT ) antibody response , 2 ) acceptability geometric mean fold rise VZV antibody response concomitant vaccination , 3 ) noninferiority concomitant versus nonconcomitant vaccination regard influenza virus strain-specific GMT antibody response .</brief_summary>
	<brief_title>Study Evaluate Immunogenicity , Safety , Tolerability ZOSTAVAX™ Vaccine ( Zoster Vaccine Live , V211 ) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine ( Inactivated ) Participants ≥50 Years Age ( V211-062 )</brief_title>
	<detailed_description />
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Has history varicella residence VZVendemic area ≥30 year Is male , female reproductive potential , female reproductive potential negative pregnancy test agree avoid become pregnant throughout study Has history hypersensitivity vaccine component Has previously receive varicella zoster vaccine Has receive influenza vaccine 201516 season Has history Herpes zoster Has receive immunoglobulin , monoclonal antibody , blood product within 5 month study vaccination Is pregnant breastfeeding , expect conceive study Has use immunosuppressant therapy Has know suspect immune dysfunction Has experience GuillainBarré syndrome within 6 week Has severe thrombocytopenia coagulation disorder</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>